SequelSEC

Maze Therapeutics, Inc. MAZE

Biological Products, (No Diagnostic Substances) · CIK 0001842295 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-06-30
Operating income
-$48.04M
Fiscal year ended 2026-06-30
Free cash flow
-$15.16M
Fiscal year ended 2026-06-30

Maze Therapeutics, Inc. (MAZE) reported revenue of $0 and net income of -$44.73M for the fiscal year ended 2026-06-30. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Maze Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Maze Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-06-302024-12-312024-09-302024-06-30
Revenue$0$20.00M$0$0$2.50M$165.00M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$48.04M-$26.55M-$36.47M-$29.73M-$24.23M$139.56M
Net income-$44.73M-$24.21M-$33.68M-$29.58M-$24.75M$139.06M
Research & development$34.94M$34.15M$28.11M$22.22M$19.86M$19.55M
Weighted-average diluted sharesshares 59.00Mshares 53.90Mshares 43.80MUnavailableshares 2.42Mshares 4.31M
Pretax incomeUnavailableUnavailable-$33.68M-$29.85M-$25.03M$140.78M
Income tax expenseUnavailableUnavailable$0-$275.00K-$279.00K$1.73M
Diluted EPS$-0.76$-0.45$-0.77Unavailable$-10.25$3.22
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$13.10M$12.40M$8.37M$7.51M$6.87M$5.90M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Maze Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-06-302024-12-312024-09-302024-06-30
Cash & equivalents$202.64M$198.77M$264.54M$196.81M$149.61M$175.06M
Total assets$531.62M$419.71M$303.52M$240.54MUnavailableUnavailable
Current assets$420.42M$379.78M$271.15M$201.67MUnavailableUnavailable
Total liabilities$78.50M$78.01M$41.28M$43.64MUnavailableUnavailable
Current liabilities$22.96M$21.24M$19.90M$20.67MUnavailableUnavailable
Total equity incl. NCI$453.12M$341.70M$262.24M-$311.18M-$284.53M-$262.37M
Temporary (mezzanine) equityUnavailableUnavailableUnavailable$508.09MUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailable$20.00MUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$38.96M$38.83MUnavailableUnavailableUnavailableUnavailable
Accounts payable$2.21M$4.01M$3.67M$1.94MUnavailableUnavailable

Cash flow

Maze Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-06-302024-12-312024-09-302024-06-30
Operating cash flow-$15.05M-$39.11MUnavailable-$22.45M-$23.20MUnavailable
Capital expenditures$107.00K$93.00KUnavailable$605.00K$103.00KUnavailable
Investing cash flow-$128.51M$6.28MUnavailable-$605.00K-$103.00KUnavailable
Financing cash flow$147.44M$42.36MUnavailable$70.26M-$2.15MUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$9.19M$7.11MUnavailable$2.85M$2.34MUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Maze Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-06-302024-12-312024-09-302024-06-30
Free cash flow-$15.16M-$39.21MUnavailable-$23.06M-$23.31MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailable-132.8%UnavailableUnavailable-969.2%84.6%
FCF marginUnavailable-196.0%UnavailableUnavailable-932.3%Unavailable
SBC / revenueUnavailable35.5%UnavailableUnavailable93.7%Unavailable
Current ratio18.31x17.88x13.63x9.76xUnavailableUnavailable
Revenue YoY growthUnavailableUnavailable-100.0%UnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailable-990.1%Unavailable
R&D / revenueUnavailable170.7%UnavailableUnavailable794.3%11.8%
CapEx / revenueUnavailable0.5%UnavailableUnavailable4.1%Unavailable
Long-term debt / equity0.09xUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable1.2%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MAZE in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.